- Home
- KOD vs ATYR Comparison
KOD vs ATYR Comparison
Compare KOD & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- ATYR
- Stock Information
- Founded
- KOD 2009
- ATYR 2005
- Country
- KOD United States
- ATYR United States
- Employees
- KOD N/A
- ATYR N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KOD Health Care
- ATYR Health Care
- Exchange
- KOD Nasdaq
- ATYR Nasdaq
- Market Cap
- KOD 121.5M
- ATYR 126.3M
- IPO Year
- KOD 2018
- ATYR 2015
- Fundamental
- Price
- KOD $2.58
- ATYR $1.74
- Analyst Decision
- KOD Hold
- ATYR Strong Buy
- Analyst Count
- KOD 5
- ATYR 3
- Target Price
- KOD $3.25
- ATYR $20.00
- AVG Volume (30 Days)
- KOD 159.5K
- ATYR 346.7K
- Earning Date
- KOD 11-12-2024
- ATYR 11-07-2024
- Dividend Yield
- KOD N/A
- ATYR N/A
- EPS Growth
- KOD N/A
- ATYR N/A
- EPS
- KOD N/A
- ATYR N/A
- Revenue
- KOD N/A
- ATYR $588,000.00
- Revenue This Year
- KOD N/A
- ATYR N/A
- Revenue Next Year
- KOD N/A
- ATYR $2,057.88
- P/E Ratio
- KOD N/A
- ATYR N/A
- Revenue Growth
- KOD N/A
- ATYR N/A
- 52 Week Low
- KOD $1.37
- ATYR $1.08
- 52 Week High
- KOD $7.77
- ATYR $2.50
- Technical
- Relative Strength Index (RSI)
- KOD 48.33
- ATYR 43.46
- Support Level
- KOD $2.50
- ATYR $1.67
- Resistance Level
- KOD $2.64
- ATYR $1.81
- Average True Range (ATR)
- KOD 0.17
- ATYR 0.07
- MACD
- KOD 0.00
- ATYR -0.01
- Stochastic Oscillator
- KOD 47.06
- ATYR 24.14
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.